Thus, strategies for melanoma therapy should consider the mutational status, and BRAF mutant melanomas may be more sensitive to mTOR inhibition therapy alone or in combination with MAPK inhibitors, such as vemurafenib, the BRAFV 600E inhibitor already approved for the treatment of advanced melanoma (www.fda.gov). This evidence concerns the gene MTOR and melanoma.